IP Verse

A Dosing Regime And Formulations For Type B Adenoviruses - EP3007711

The patent EP3007711 was granted to Akamis BIO on Oct 21, 2020. The application was originally filed on Jun 12, 2014 under application number EP14736650A. The patent is currently recorded with a legal status of "Revoked".

EP3007711

AKAMIS BIO
Application Number
EP14736650A
Filing Date
Jun 12, 2014
Status
Revoked
Feb 21, 2025
Grant Date
Oct 21, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DEHNSJul 19, 2021DEHNSADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO0074722
DESCRIPTIONWO2005118825
DESCRIPTIONWO2006008513
DESCRIPTIONWO2008080003
DESCRIPTIONWO2010038086
DESCRIPTIONWO2010067041
DESCRIPTIONWO2010067081
DESCRIPTIONWO2011048111
DESCRIPTIONWO9819710
INTERNATIONAL-SEARCH-REPORTWO2005010149
INTERNATIONAL-SEARCH-REPORTWO2005118825
INTERNATIONAL-SEARCH-REPORTWO2008080003
OPPOSITIONWO2005010149
OPPOSITIONWO2005118825
OPPOSITIONWO2008080003

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "FOR IMMEDIATE RELEASE PSIOXUS THERAPEUTICS TO RELEASE STUDY RESULTS OF ONCOLYTIC VACCINE ENADENOTUCIREV IN CANCER PATIENTS Phase I Studies to be Presented at 2014 ASCO Annual Meeting", 2014 ASCO Annual meeting, (20140413), pages 1 - 3, XP055830428-
OPPOSITION- Calvo, Et Al, "A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors.", ASCO meeting library, (20140603), pages 1 - 2, XP055830433-
OPPOSITION- DEMERS et al., "Pharmacologic Indicators of Antitumor Efficacy for Oncolytic Virotherapy", CANCER RESEARCH, US, (20030715), vol. 63, no. 14, ISSN 0008-5472, pages 4003 - 4008, XP055164224-
OPPOSITION- Garcia, Et Al, "A phase 1 mechanism of action study of intratumoral or intravenous administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumor.", ASCO Meeting Library, (20140603), pages 1 - 2, XP055830441-
OPPOSITION- RAKI et al., "Oncolytic adenovirus Ad5/3-DELTA24 and chemotherapy for treatment of orthotopic ovarian cancer", GYNECOLOGIC ONCOLOGY, LONDON, GB, (20071022), vol. 108, no. 1, doi:10.1016/j.ygyno.2007.09.013, ISSN 0090-8258, pages 166 - 172, XP022413063
OPPOSITION- SMALL et al., "A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer", MOLECULAR THERAPY, GB, vol. 14, no. 1, doi:10.1016/j.ymthe.2006.02.011, ISSN 1525-0016, pages 107 - 117, XP005524567
OPPOSITION- DI et al., "Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood", GENE THERAPY, (20140400), vol. 21, no. 4, doi:10.1038/gt.2014.2, ISSN 0969-7128, pages 440 - 443, XP055148732
OPPOSITION- Hemminki Otto, Et Al, "Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer", Molecular Therapy, Elsevier Inc., US, US, (20120901), vol. 20, no. 9, doi:10.1038/mt.2012.115, ISSN 1525-0016, pages 1821 - 1830, XP055830443
OPPOSITION- RUSSE LL et al., "Oncolytic virotherapy", NATURE BIOTECHNOLOGY, (20120710), vol. 30, no. 7, doi:10.1038/nbt.2287, ISSN 1087-0156, pages 658 - 670, XP055164204
OPPOSITION- Reid Tony, Warren Robert, Kirn David, "Intravascular adenoviral agents in cancer patients: Lessons from clinical trials", Cancer Gene Therapy, Appleton & Lange, New York, New York, (20021201), vol. 9, no. 12, doi:10.1038/sj.cgt.7700539, ISSN 0929-1903, pages 979 - 986, XP055830452
OPPOSITION- Nemunaitis J, Et Al, "Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity", Gene Therapy, Nature Publishing Group, London, GB, GB, (20010501), vol. 8, no. 10, doi:10.1038/sj.gt.3301424, ISSN 0969-7128, pages 746 - 759, XP055830445
OPPOSITION- VOGELS R, ET AL., "REPLICATION-DEFICIENT HUMAN ADENOVIRUS TYPE 35 VECTORS FOR GENE TRANSFER AND VACCINATION: EFFICIENT HUMAN CELL INFECTION AND BYPASS OF PREEXISTING ADENOVIRUS IMMUNITY", Journal of Virology, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, US, (20030801), vol. 77, no. 15, doi:10.1128/JVI.77.15.8263-8271.2003, ISSN 0022-538X, pages 8263 - 8271, XP009021328
OPPOSITION- Laurie Scott A.et al, "A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization", CLINICAL CANCER RESEARCH, American Association for Cancer Research, US, US, (20060415), vol. 12, no. 8, doi:10.1158/1078-0432.CCR-05-2038, ISSN 1078-0432, pages 2555 - 2562, XP055830449
OPPOSITION- Hotte Sébastien J., Et Al, "An Optimized Clinical Regimen for the Oncolytic Virus PV701", CLINICAL CANCER RESEARCH, American Association for Cancer Research, US, US, (20070201), vol. 13, no. 3, doi:10.1158/1078-0432.CCR-06-1817, ISSN 1078-0432, pages 977 - 985, XP055830447
OPPOSITION- KUHN IRENE et al., "Directed evolution generates a novel oncolytic virus for the treatment of colon cancer", PLOS ONE, (20080618), vol. 3, no. 6, doi:10.1371/journal.pone.0002409, ISSN 1932-6203, pages e2409/1 - e2409/11, XP009107025
OPPOSITION- Riedmann Eva M., "Human Vaccines: News", Human vaccines & immunotherapeutics, Taylor & Francis, US, US, (20121124), vol. 8, no. 11, doi:10.4161/hv.22753, ISSN 2164-5515, pages 1550 - 1553, XP055830423

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents